SCHEMBL3463522

SCHEMBL3463522

CCCCCC(C=O)C=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ADH1B P00325 2/20 0.46
ADH1C P00326 2/20 0.46
ADH1A P07327 2/20 0.46
ADH4 P08319 2/20 0.46
ADH7 P40394 2/20 0.46
MAPT P10636 2/20 0.45
TRPA1 O75762 1/20 0.45
DDAH1 O94760 1/20 0.45
GAPDH P04406 1/20 0.45
OPRM1 P35372 1/20 0.42
FDPS P14324 4/20 0.41
GPR84 Q9NQS5 3/20 0.39
FFAR1 O14842 1/20 0.39
CA1 P00915 1/20 0.39
EPHX1 P07099 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.38
LAP3 P28838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10432807 0.97 ADH1B (0.50) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL7104793 0.97 ADH1B (0.50) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL17509727 0.97 ADH1B (0.50) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL9576172 0.97 ADH1B (0.50) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL28582956 0.97 ADH1B (0.50) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL14010386 0.92
SCHEMBL28172141 0.87 TSHR (0.54) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL361635 0.85 TSHR (0.41) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL28011570 0.85 ADH1B (0.45) TSHRSMN1; SMN2ADH1BADH1CADH1A
SCHEMBL11870095 0.84 ADH1B (0.44) TSHRSMN1; SMN2ADH1BADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3328427-B1 ANTIBODY DERIVATIVES WITH CONDITIONALLY ENABLED EFFECTOR FUNCTION MASSACHUSETTS GEN HOSPITAL (US) 2024-05-29 EP disclosed
US-20230303709-A1 Antibody Derivatives with Conditionally Enabled Effector Function THE GENERAL HOSPITAL CORPORATION 2023-09-28 US disclosed
US-20180215831-A1 Antibody Derivatives with Conditionally Enabled Effector Function THE GENERAL HOSPITAL CORPORATION 2018-08-02 US disclosed
EP-3344678-A1 AMINE FOR LOW-EMISSION EPOXY RESIN COMPOSITIONS Sika Technology AG (CH) 2018-07-11 EP disclosed
EP-3328427-A1 ANTIBODY DERIVATIVES WITH CONDITIONALLY ENABLED EFFECTOR FUNCTION The General Hospital Corporation (US) 2018-06-06 EP disclosed
EP-3180382-A1 AMINE FOR LOW-EMISSION EPOXY RESIN COMPOSITIONS Sika Technology AG (CH) 2017-06-21 EP disclosed
EP-2046375-B1 METHODS AND COMPOSITIONS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING MASSACHUSETTS GEN HOSPITAL (US) 2017-04-05 EP disclosed
WO-2017037070-A1 AMINE FOR LOW-EMISSION EPOXY RESIN COMPOSITIONS SIKA TECHNOLOGY AG (CH) 2017-03-09 WO disclosed
WO-2017019729-A1 ANTIBODY DERIVATIVES WITH CONDITIONALLY ENABLED EFFECTOR FUNCTION THE GENERAL HOSPITAL CORPORATION (US) 2017-02-02 WO disclosed
WO-2016023837-A1 AMINE FOR LOW-EMISSION EPOXY RESIN COMPOSITIONS SIKA TECHNOLOGY AG (CH) 2016-02-18 WO disclosed
CN-101821239-A 3-alkoxyl group-1-phenylpyrazole derivatives and noxious organism control agent KUMIAI CHEMICAL INDUSTRY CO 2010-09-01 CN disclosed
EP-2178559-A2 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS The General Hospital Corporation (US) 2010-04-28 EP disclosed
US-20100055761-A1 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING THE GENERAL HOSPITAL CORPORATION (US) 2010-03-04 US disclosed
EP-2046375-A2 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING The General Hospital Corporation (US) 2009-04-15 EP disclosed
WO-2009014650-A2 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS THE GENERAL HOSPITAL CORPORATION (US) 2009-01-29 WO disclosed
WO-2008011157-A2 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING THE GENERAL HOSPITAL CORPORATION (US) 2008-01-24 WO disclosed
EP-0306521-B1 ETHINE DERIVATIVES AS COMPOUNDS OF LIQUID CRYSTAL PHASES MERCK PATENT GmbH (DE) 1991-10-16 EP disclosed
EP-0351641-A1 1-Phenylpyrrole NIHON BAYER AGROCHEM K.K. (JP) 1990-01-24 EP disclosed
EP-0306521-A1 ETHINE DERIVATIVES AS COMPOUNDS OF LIQUID CRYSTAL PHASES. MERCK PATENT GMBH (DE) 1989-03-15 EP disclosed
WO-1988007516-A1 ETHINE DERIVATIVES AS COMPOUNDS OF LIQUID CRYSTAL PHASES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1988-10-06 WO disclosed